Current overview of the role of immunotherapy in onco‑urology
Authors:
Jiřina Bartůňková; Zuzana Střížová; Daniel Smrž
Authors‘ workplace:
Ústav imunologie 2. lékařské fakulty a Fakultní nemocnice v Motole, Praha
Published in:
Ces Urol 2022; 26(3): 165-173
Category:
Review articles
Overview
Immunotherapy was shown to be a crucial therapeutic modality in the treatment of cancer. The efficacy of immunotherapy in late stage clinical trials has allowed immunotherapy to become a standard of care for first-line therapy in onco-urology. The major therapeutic impact is currently attributed to the effects of immune checkpoint inhibitors (ICIs). ICIs are monoclonal antibodies that target the inhibitory receptors of T cells, thus allowing a significant potentiation of anti-cancer T cell cytotoxicity. Since the approach is rather non-specific, several adverse events (AEs) were reported. These AEs are mostly of autoimmune nature but can be treated and clinically managed. Despite immunotherapy being largely efficient in certain cancer types, other malignancies, such as prostate cancer, still exhibit only limited treatment responses. For that reason, other immunotherapeutic approaches are currently being investigated in prostate cancer. Furthermore, combinatorial approaches bring a great deal of promise. Currently, the major goal is to understand immunotherapeutic combinations that have the highest potential to effectively treat cancer and have the lowest frequency of AEs. Moreover, the quality of life in patients with late-stage cancer is of highest priority and must be ensured in patients treated with combination of different therapeutic modalities.
Keywords:
immunotherapy – checkpoint inhibitors – Prostate carcinoma – kidney cancer – urothelial cancer
Sources
1. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral‑based PSA‑targeted immunotherapy in metastatic castration‑resistant prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(7): 1099–105.
2. Twomey JD, Zhang B. Cancer Immunotherapy Update: FDA‑Approved Checkpoint Inhibitors and Companion Diagnostics. The AAPS journal. 2021; 23(2): 39.
3. Subiela JD, Rodriguez Faba O, Aumatell J, et al. Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette‑Guerin immunotherapy. BJU international 2021.
4. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12): 5451–8.
5. Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res. 2000; 60(13): 3577–83.
6. ImmunityBio. 14. 2. 2022, ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer (online). Dostupné z: https://immunitybio.com/immunitybio‑announces‑over- 24-months‑median‑duration‑of‑complete‑remission‑with- 100-%NBIMC‑CIS.
7. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD‑L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in pharmacology. 2017; 8: 561.
8. Kumar V, Chaudhary N, Garg M, et al. Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in pharmacology. 2017; 8: 311.
9. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349): 409–13.
10. Thana M, Wood L. Immune checkpoint inhibitors in genitourinary malignancies. Current onkology. 2020; 27(Suppl. 2): S69–S77.
11. Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. Human vaccines & immunotherapeutics. 2020; 16(10): 2389–402.
12. Razzaghdoust A, Rahmatizadeh S, Mofid B, et al. Data‑Driven Discovery of Molecular Targets for Antibody‑Drug Conjugates in Cancer Treatment. BioMed research international. 2021; 2021: 2670573.
13. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348(6230): 62–8.
14. Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric Antigen Receptor T‑Cell Therapy in Metastatic Castrate‑Resistant Prostate Cancer. Cancers. 2022; 14(3).
15. Madan RA, Antonarakis ES, Drake CG, et al. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel‑T. Journal of the National Cancer Institute. 2020; 112(6): 562–73.
16. Vogelzang NJ, Beer TM, Gerritsen W, et al. Efficacy and Safety of Autologous Dendritic Cell‑Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration‑Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. JAMA onkology. 2022.
17. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration‑Resistant Prostate Cancer. The New England journal of medicine. 2021; 385(12): 1091–103.
18. Schulz GB, Black PC. Combination therapies involving checkpoint‑inhibitors for treatment of urothelial carcinoma: a narrative review. Translational andrology and urology. 2021; 10(10): 4014–21.
19. Kwon WA, Seo HK. Emerging agents for the treatment of metastatic urothelial cancer. Investigative and clinical urology. 2021; 62(3): 243–55.
20. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. The New England journal of medicine. 2021; 384(12): 1125–35.
21. Bansal A, Singh J, Kaur S, Kaur N. Enfortumab Vedotin‑Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction. Indian dermatology online journal. 2022; 13(1): 128–30.
22. Schmidinger M, Resch I, Fajkovic H, et al. Dual immune check point blockade or immune check point‑tyrosine kinase inhibitor combination: as a first‑line treatment in metastatic renal cell carcinoma? Current opinion in urology. 2021; 31(3): 270–5.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2022 Issue 3
Most read in this issue
- Nekrolog prof. MUDr. Ondřej Hes, Ph.D.
- Evaluation of pain of transperineal prostate biopsy under local anaesthesia
- Current overview of the role of immunotherapy in onco‑urology
- Intravesical, radiofrequency-induced chemohyperthermia in the treatment of non-muscle invasive bladder cancer